LEP Biomedical is developing a dissolvable implant that replaces weeks of self-administered eye drops after glaucoma surgery, aiming to fix the compliance problems that drive surgical failure rates as high as 40%.
A Bausch + Lomb drug from a 2025 acquisition missed primary and secondary goals of a Phase 2 test in glaucoma. Bausch now plans to develop this drug for geographic atrophy, aiming to succeed where Allergan, now an AbbVie subsidiary, fell short in the clinic.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Perfuse Therapeutics brings Bayer an eye drug administered via an implant that controls the release of the therapy. This program is in mid-stage clinical development for glaucoma and diabetic retinopathy.
The technologies and techniques developed for eye transplantation and nerve regeneration may have significant translational potential for other biomedical needs including: spinal cord injury, central nervous system regeneration, retinal cell and tissue transplantation, and other forms of organ and tissue transplantation.
Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
The company's technology for screening diabetic retinopathy was granted "Breakthrough Device" designation and is able to provide a clinical decision, instead of simply a recommendation to the physician.
Orange County, California-based Glaukos announced that the approval indicates use of the device, along with cataract surgery, makes it the first micro-invasive glaucoma surgery in Japan.
Applications and video games could be the next best way to assess eye health. That's the approach Vizzario it taking.
InnFocus has raised funds to further develop its InnFocus MicroShunt glaucoma drainage system to treat early, moderate, and late stage primary open angle glaucoma.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.